Microbiological profiles and prognostic factors of infection mortality in febrile neutropenic children with malignancy
Abstract
Background Post-chemotherapy febrile neutropenia results in high morbidity and mortality in children with malignancy. Many prognostic factors, such as microorganism patterns, as well as the use of antibiotics and antifungals can affect the outcomes. However, limited study is available in Indonesia.
Objective To determine the microbial profiles, antibiotic sensitivity, and other factors that influence mortality from febrile neutropenia in pediatric malignancies with infections.
Methods This retrospective cohort and descriptive study of 180 children with 252 episodes of neutropenic fever was done in Cipto Mangunkusumo Hospital, Jakarta, between 2015 and 2017. Medical history of possible predictive prognostic factors, including microorganism patterns and antibiotic sensitivity, were recorded. Prognostic factors were analyzed using multivariate logistic regression tests.
Results The most common bacteria was Gram-negative (54.5%), while Candida sp. was the most common fungal infection (82.5%). Klebsiella sp. was mainly sensitive to amikacin (85.71%), while Pseudomonas aeruginosa was sensitive to ceftazidime (75%), as well as amikacin and gentamicin (100% sensitivity in combination). Staphylococcus sp. was mainly sensitive to amoxi-clav and ampi-sulbactam (76.9%). Almost all fungal groups were susceptible to fluconazole, ketoconazole, voriconazole (80-100%). Prognostic factors that increased mortality risk were central venous cannulation (RR 1.947; 95%CI 1.114 to 3.402), wasting (RR 1.176; 95%CI 1.044 to 1.325), severe wasting (RR 1.241; 95%CI 0.975 to 1.579), and hematologic malignancies (RR 0.87; 95%CI 0.788 to 0.976).
Conclusion Central venous cannulation and wasting are significant prognostic factors of increased mortality in children with febrile neutropenia. Gram negative bacteria along with Candida sp. is the most common pathogen in such condition.
References
2. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol. 2012;52:203-8. DOI: 10.1007/s12088-011-0210-6.
3. Ozdemir N, Tuysuz G, Celik N, Yantri L, Erginoz E, Apak H, et al. Febrile neutropenia in children with acute lymphoblastic leukemia: single center experience. Turk Pediatri Ars. 2016;51:79-86. DOI: 10.5152/TurkPediatriArs.2016.2757.
4. Prasad M, Chinnaswamy G, Arora B, Vora T, Hawaldar R, Banavali S. Risk predictors for adverse outcome in pediatric febrile neutropenia: Single center experience from a low and middle-income country. Indian J Cancer. 2014;51:432-7. DOI: 10.4103/0019-509X.175321.
5. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-70. DOI: 10.1097/01.mph.0000212996.94929.0b.
6. Hadinegoro SRS. Demam pada pasien neutropenia. Sari Pediatri. 2002;4:235 - 41. DOI: 10.14238/sp3.4.2002.235-41.
7. Tim PPRA Departemen IKA RSCM. Pedoman penggunaan antibiotik empiris Departemen Ilmu Kesehatan Anak. Jakarta: Departemen IKA RSCM; 2016. p. 1-2.
8. Badr M, Hassan T, Sakr H, Karam N, Rahman DA, Shahbah D, et al. Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: risks and consequences. Mol Clin Oncol. 2016;5:300-6. DOI: 10.3892/mco.2016.957.
9. Kar YD, Ozdemir ZC, Bor O. Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. Turk Pediatri Ars. 2017;52:213-20. DOI: 10.5152/TurkPediatriArs.2017.5312.
10. Jabeen S, Haque M, Islam MJ, Talukder MH. Profile of paediatric malignancies: a five year study. J Dhaka Med Coll. 2010;19:33-8. DOI: 10.3329/jdmc.v19i1.6249.
11. Rosenblum J, Lin J, Kim M, Levy AS. Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative. Pediatr Blood Cancer. 2013;60:923-7. DOI: 10.1002/pbc.24358.
12. Sjakti HA, Gatot D, Windiastuti E. Hasil pengobatan leukemia mieloblastik akut pada anak. Sari Pediatri. 2012;14:40-5.
13. Meidani M, Rostami M, Moulaee S. Blood culture in neutropenic patients with fever [Letter to the editor]. [cited 2012 January 9]. Int J Prev Med,. 142. Avalaible from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278881/
14. Adrienta, Widiastuti E, Handryastuti S. Etiologi demam neutropenia pada anak dengan keganasan dan penggunaan skor klasifikasi Rondinelli. Sari Pediatri. 2014;16:229-35. DOI: 10.14238/sp16.4.2014.229-35.
15. Ozdemir ZC, Koc A, Aycicek A. Microorganisms isolated from cultures and infection focus and antibiotic treatments in febrile neutropenic children from Sanliurfa, Turkey. Turk J Pediatr. 2016;58:47-53. DOI: 10.24953/turkjped.2016.01.007.
16. Gupta S, Bonilla M, Gamero M, Fuentes SL, Caniza M, Sung L. Microbiology and mortality of pediatric febrile neutropenia in El Salvador. J Pediatr Hematol Oncol. 2011;33:276-80. DOI: 10.1097/MPH.0b013e31820ff632.
17. Hautala T, Ikaheimo I, Husu H, Saily M, Siitonen T, Koistinen P, et al. A cluster of Candida krusei infections in a haematological unit. BMC Infect Dis. 2007;7:97. DOI: 10.1186/1471-2334-7-97.
18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-93. DOI: 10.1093/cid/cir073.
19. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-9.DOI: 10.1016/s0002-9343(99)00457-x.
20. Haddadin Y, Annamaraju P, Regunath H. Central line associated blood stream infections. [Updated 2021 Aug 11]. In: StatPearls [Internet]. [cited 2020 Jan 5]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430891.
21. Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012;4:e9. DOI: 10.4081/pr.2012.e9.
22. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011;56:1092-7. DOI: 10.1002/pbc.23005.
23. Triarico S, Rinninella E, Cintoni M, Capozza MA, Mastrangelo S, Mele MC, et al. Impact of malnutrition on survival and infections among pediatric patients with cancer: a retrospective study. Eur Rev Med Pharmacol Sci. 2019;23:1165-75. DOI: 10.26355/eurrev_201901_17009.
24. Agnes M, Widjajanto PH, Damayanti W. Impact of malnutrition on febrile neutropenia in children with acute lymphoblastic leukemia during induction phase chemotherapy. Paediatr Indones. 2018;58:298-302.DOI: 10.14238/pi58.6.2018.298-304.
Copyright (c) 2021 Yuni Astria, Hindra Irawan Satari, Hartono Gunardi, Hikari Ambara Sjakti
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2021-10-04
Published 2021-10-04
